Search | Clinical Trials Finder

Conditions: Mitigation of Immune Function Decrements in Response to Stress
Interventions: Immune-enhancing nutritional beverage, Probiotics (BB-12), Placebo (for nutritional beverage and probiotic); Dietary Supplement
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Weight Management, Stress
Interventions: Ashwagandha 300 mg standardized root extract, Identical placebo capsule.; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 19 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C
Interventions: AdCh3NSmut1, MVA-NSmut, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • Albuquerque, New Mexico

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Galvokimig, Placebo; Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Brandon, Florida • Plantation, Florida • DuBois, Pennsylvania + 1 more

Conditions: Hypochondroplasia
Interventions: infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: New Biomarkers for Measuring Vitamin D Level
Interventions: Vitamin D Supplementation, Placebo, Calcium; Dietary Supplement · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 444 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Tinnitus, Chronic Subjective Tinnitus
Interventions: Nicotine polacrilex gum 4 mg, Placebo gum; Drug · Other
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C
Interventions: TMC435, TVR; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 32
States / cities: Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more

Conditions: Cushings Disease
Interventions: osilodrostat, LCI699 matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 12
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Cognitive Enhancement During Exercise
Interventions: Huperzine A, Placebo; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Autism
Interventions: Omega-3 Fatty Acids; Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 8 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Visceral
Interventions: [U-13C3] glycerol, Empagliflozin, Placebo (for Empagliflozin); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gastroenteritis Escherichia Coli
Interventions: Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions: Levocarnitine tartrate, cilostazol; Dietary Supplement · Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more

Conditions: Keratoconus
Interventions: Antioxidants (Vitamins A,C,E) plus GSH, Placebo, Centrum, Dietary Sources; Other · Dietary Supplement · Combination Product
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Bacterial Infections
Interventions: TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alcohol Abuse, Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo medication; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Relapsing Multiple Sclerosis
Interventions: SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Schizophrenia
Interventions: PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Sickle Cell Disease
Interventions: L-Arginine Hydrochloride, Normal saline; Drug · Other
Lead sponsor: Claudia R. Morris; Other
Eligibility: 3 Years to 21 Years
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Escondido, California • Greenbrae, California • Walnut Creek, California + 11 more

Conditions: Ventilator-Associated Pneumonia
Interventions: Doripenem, Imipenem-Cilastatin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 17
States / cities: Jonesboro, Arkansas • Newark, Delaware • Washington D.C., District of Columbia + 14 more

Search by objective public record fields.

Nutrition Interventions to Support the Immune System in Response to Stress

Ashwagandha Extract for Weight and Stress Management in Overweight and Obese Adults

Staged Phase I/II Hepatitis C Prophylactic Vaccine

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

An Interventional Study of Infigratinib in Children With Hypochondroplasia

A New Paradigm for Vitamin D Sufficiency

Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise

Omega-3 Fatty Acids for Autism Treatment

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

Evaluation of Cilostazol in Combination With L-Carnitine

The Role of Antioxidant Supplementation in Keratoconus Patients

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia